Characteristics and significance of peripheral blood T-cell receptor repertoire features in patients with indeterminate lung nodules  

作　　者：Huaichao Luo Ruiling Zu Ziru Huang Yingqiang Li Yulin Liao Wenxin Luo Peng Zhou Dongsheng Wang Shifu Chen Weimin Li Jian Huang 

机构地区：[1]School of Life Science and Technology,University of Electronic Science and Technology of China,Chengdu,Sichuan,China [2]Department of Clinical Laboratory&Division of Radiology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,China [3]HaploX Biotechnology Co.,Ltd,Shenzhen,China [4]Department of Respiratory and Critical Care Medicine,West China Hospital,West China Medical School,Sichuan University,Chengdu,610041,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第11期4007-4010,共4页信号转导与靶向治疗（英文）

基　　金：Sichuan Medical Association Research project(S20087);Sichuan Cancer Hospital Outstanding Youth Science Fund(YB2021033);National Natural Science Foundation of China(62071099);supported by Medico-Engineering Cooperation Funds from University of Electronic Science and Technology of China(No.ZYGX2022YGRH004).

摘　　要：Dear Editor,Dear Editor,Lung cancer is one of the most common cancers and a leading cause of cancer-related deaths.T cells are known to play a significant role in the destruction of cancer cells.T cells have therefore become the focus of lung cancer immunotherapy.T-cell receptors(TCRs)can recognize antigenic peptides presented by HLA proteins.TCRs are distinct individually and vary with pathophysiological condition,so T cells can respond to a wide range of antigens.TCR repertoire diversity reflects the potential for cellular immunity,and several studies have demonstrated that complementarity determining region 3(CDR3β)diversity is important in cancer therapy and prognosis.1 Liu et al.have reported that the CDR3βdiversity of patients with advanced lung cancer differs significantly from that of healthy individuals.

关 键 词：CDR3 LUNG PATIENTS 

分 类 号：R734.2[医药卫生—肿瘤]